What are the DSM-5 subtypes of bipolar disorder?
The DSM-5-TR defines three primary bipolar subtypes, each with distinct diagnostic criteria and treatment implications:
- Bipolar I disorder — at least one full manic episode lasting seven days or requiring hospitalization. Depressive episodes are common but not required for diagnosis. Manic episodes include elevated or irritable mood, decreased need for sleep, grandiosity, racing thoughts, distractibility, and high-risk behavior.
- Bipolar II disorder — at least one hypomanic episode (four days or longer, without psychosis or hospitalization) plus at least one major depressive episode. Depression typically dominates the clinical picture and accounts for most treatment-seeking.
- Cyclothymic disorder — at least two years of fluctuating hypomanic and depressive symptoms that do not meet full episode criteria, with symptoms present at least half the time.
Accurate subtype identification drives medication choice, prognosis estimation, and the level of monitoring required.
Which mood stabilizer medications are used?
Bipolar pharmacotherapy is built on four FDA-approved medication classes, selected based on episode polarity, prior response, comorbidities, and side-effect tolerability:
- Lithium — the gold-standard mood stabilizer, with the strongest evidence for relapse prevention and suicide reduction. The Cipriani et al. 2013 BMJ meta-analysis confirmed lithium's suicide-prevention effect. Requires renal and thyroid monitoring and serum level checks.
- Valproate (Depakote) — effective for acute mania and mixed episodes. Requires liver function and platelet monitoring. Contraindicated in pregnancy due to teratogenicity.
- Lamotrigine (Lamictal) — first-line for bipolar depression maintenance, particularly in Bipolar II. Slow titration required due to Stevens-Johnson syndrome risk.
- Atypical antipsychotics — quetiapine, olanzapine, aripiprazole, risperidone, and lurasidone. Quetiapine and lurasidone carry FDA approval for bipolar depression. Metabolic monitoring is required.
Antidepressant monotherapy is avoided due to risk of inducing manic switch or rapid cycling, per APA Practice Guideline.
Questions About Which mood stabilizer medications?
Call our 24/7 admissions line or verify your insurance online.
Why is bipolar disorder common with substance use disorder?
SAMHSA reports that 50–60% of patients with bipolar disorder also meet criteria for substance use disorder over their lifetime — among the highest comorbidity rates of any psychiatric condition. The drivers are biological, behavioral, and circumstantial.
Biologically, both disorders involve dopaminergic and reward-circuit dysregulation; shared genetic loci have been identified in family and twin studies. Behaviorally, mania increases impulsivity and high-risk behavior, including substance use; depression increases self-medication. Circumstantially, sleep disruption, financial chaos, and interpersonal damage during mood episodes raise exposure to substances.
Integrated treatment — psychiatric medication management plus addiction-focused therapy in the same clinical program — produces better outcomes than sequential or parallel care, documented in SAMHSA TIP 42.
“Bipolar disorder with co-occurring substance use is one of the highest-risk presentations in psychiatry. We coordinate mood stabilizer prescribing, CBT for bipolar, IPSRT, and SUD treatment under one clinical plan — because sequential care does not work for this population.”
What does bipolar treatment look like in PHP and IOP?
Bipolar treatment at Ascend is delivered across PHP and IOP through four coordinated components:
- Psychiatric medication management — initial 60-to-90-minute evaluation with weekly follow-up in PHP and biweekly follow-up in IOP. Mood charting, side-effect review, and serum level monitoring for lithium and valproate.
- CBT for bipolar disorder — manualized protocols targeting prodromal symptom recognition, sleep regulation, adherence, and depressive cognitive distortions.
- Interpersonal and Social Rhythm Therapy (IPSRT) — stabilization of daily routines, sleep-wake cycles, and social rhythms, validated for bipolar maintenance.
- Dual diagnosis programming — integrated SUD treatment when substance use co-occurs, including MAT when indicated for opioid or alcohol use disorder.
Family education is included because relapse-warning-sign recognition by family members is one of the strongest predictors of early intervention.
